

thrombocytopenia and leukopenia), vasculitis, hepatitis and aseptic meningitis. There were no deaths in our cohort.

	Children (n = 52)	Adults (n = 160)	P-value
Age, years	8.8 ± 4.1	39 ± 10.7	
Male sex	31 (59.6%)	26 (12.3%)	0.0001
Clinical presentation			
Biphasic presentation	8 (15.4%)	48 (30.0%)	0.0460
Fever	26 (50.0%)	110 (68.7%)	0.0194
Rash	51 (98.1%)	127 (79.4%)	0.0008
Myalgia	5 (9.6%)	50 (31.2%)	0.0017
Arthralgia	9 (17.3%)	100 (62.5%)	0.0001
Headache	3 (5.8%)	34 (21.2%)	0.0107
"Slapped cheeks"	29 (55.8%)	24 (15.0%)	0.0001
Peripheral edema	6 (11.5%)	63 (39.4%)	0.0001
Anemia	4 (7.7%)	19 (11.8%)	0.6076
Leukopenia	1 (1.9%)	23 (14.5%)	0.0111
Thrombocytopenia	4 (7.7%)	35 (21.8%)	0.0231
Hepatitis	1 (1.9%)	11 (6.87%)	0.3011
Vasculitis	1 (1.9%)	2 (1.25%)	0.5721
Other	2 (3.8%)	3 (1.9%)	0.5982

Conclusion. Parvovirus B19 infection has different clinical presentation, laboratory findings and complications in children and adults. Since the diversity of the clinical manifestations in adults may be misleading, the infection in adults should be suspected when disease is prevalent in children.

Disclosures. All authors: No reported disclosures.

1055. Haemophilus Influenzae Type B Invasive Disease in a Pediatric Hospital of Argentina

Eduardo Walter Yfran EW, MD¹; Fausto M Ferolla, MD²; Carolina Carballo, MD²; María Marco Del Pont, MD³; Carolina Acosta IV, MD⁴; Marina Elisa Pasinovich, MD⁵; Carlos Mauricio Vergara Lobo, MD⁶; Claudia I Cazes, MD⁷; María Laura Praino, MD⁸; Christian Campoverde, MD⁹; María M Contrini, MD¹⁰ and Eduardo L Lopez, MD¹¹; ¹Hospital de Niños "Ricardo Gutiérrez", Infectious Diseases Department, Buenos Aires, Argentina, ²Infectious Disease Department, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina, ³Hospital de Niños "Ricardo Gutiérrez", Infectious Diseases Department, Buenos Aires, Argentina, ⁴hospital de niños ricardo gutierrez departamento de infectología, Buenos aires, Argentina, ⁵Hospital de Niños Dr. Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Infectología, Hospital de Niños "Ricardo Gutiérrez", Universidad de Buenos Aires, Buenos Aires, Argentina, ⁷Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina, ⁸Infectious Diseases, Hospital Ricardo Gutiérrez, Buenos Aires, Argentina, ⁹Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina, ¹⁰Infectious Diseases, Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina, ¹¹Department of Medicine, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina

Session: 140. Assorted Pediatric Vaccines

Friday, October 6, 2017: 12:30 PM

Background. Since The vaccination strategy is a three-dose primary series (at two, Active surveillance is important to opportunely detect variations on these trends.

Methods. Cross-sectional study, including all hospitalized patients with Hib infection since 2012 to May 2017 at Hospital de Niños "Ricardo Gutiérrez" in Buenos Aires, Argentina.

Results. Twenty previously healthy children were admitted. Male/female ratio 1.8:1. Median age: 12 (range 45 days-114) months; 85% younger than 2 years and 35% younger than 6 months. Nine patients (45%) had complete vaccination schedule, with three or more doses of DTP-Hib-HBV vaccine. Hospitalization Hib infections by year in Table 1.

Year	Hib admissions (n)	Total hospital admissions (n)	Hospitalization rates (per 100.000 admissions/year)
2012	1	9,764	1,02
2013	2	9,304	2,15(IC 95% 0.26–7.76)
2014	3	9,066	3,31(IC95% 0.68–13.81)
2015	6	9,450	6,35 (IC 95% 2.33–13.81)
2016	8	9,780	8,18 (IC 95% 3.5– 6.11)

Clinical presentation: meningitis (14/20), pneumonia (6/20) and arthritis (5/20), osteomyelitis (1/20). All patients with meningitis, 25% of pneumonias and 50% of arthritis had positive blood cultures. Hib was isolated from blood in 17/20 cases, cerebrospinal fluid in 7/14, joint fluid in 3/5 and pleural fluid in 2/6. Median WBC: 12,400/mm³ (1,600–42,900) and median C-reactive protein level 111 mg/L (7–358). Median days of hospitalization was 13 (8–40). Nine patients required intensive care, four of them required mechanical ventilation. None patients died. Immunological studies ruled out immunodeficiency in 10 patients, although four continues under study.

Conclusion. (i) Burden of invasive Hib infections have increased over the last few years in our setting. (ii) Most of patient had adequate immunization schedule for age; (iii) Surveillance studies should be continued to confirm these preliminary results as well as to evaluate possible causes.

Disclosures. All authors: No reported disclosures.

1056. Single-Dose Universal Hepatitis A Immunization in 1-Year-Old Infants in Argentina: High Prevalence of Protective Antibodies up to 11 Years Following Vaccination

Analia Uruña, MD¹; Jorge González, PhD²; María Eugenia Perez Carrega, MD³; Analia Rearte, MD³; Andrea Uboldi, MD⁵; Rogelio Calli, MD⁶; María Cristina Cañero-Velasco, MD⁷ and Carla Vizzotti, MD⁸; ¹Ministerio de Salud de la Nación (2009–2016), Buenos Aires, Argentina, ²Laboratorio Nacional de Referencia de Hepatitis Virales. INEI-ANLIS "Dr. Carlos Malbrán", Buenos Aires, Argentina, ³Ministerio de Salud de la Nación (2011–2016), Buenos Aires, Argentina, ⁴Ministerio de Salud de la Nación, Buenos Aires, Argentina, ⁵Ministerio de Salud de la Provincia de Santa Fe, Programa Ampliado de Inmunizaciones, Santa Fe, Argentina, ⁶Dirección de Epidemiología del Ministerio de Salud Pública de la Provincia de Tucumán, Tucumán, Argentina, ⁷Hospital de Niños de San Justo, Buenos Aires, Argentina, ⁸Ministerio de Salud de la Nación (2007–2016), Buenos Aires, Argentina

Session: 140. Assorted Pediatric Vaccines

Friday, October 6, 2017: 12:30 PM

Background. Single-dose Hepatitis A Virus (HAV) vaccination was implemented for all Argentinean children aged 12 months in 2005, instead of the standard two-dose schedule. Previous studies demonstrated a dramatic decline in HAV infection rates, fulminant hepatitis, and liver transplantation along with low viral circulation and high prevalence of protective antibody response 8 years following the intervention. This study assessed long-term seroprotection against HAV after vaccination with this novel scheme.

Methods. Children who received one dose of HAV vaccine at 1 year of age, at least nine years before enrollment, were included at three centers in Argentina between May 2015 and April 2016. Demographic and socio-economic characteristics of the child, mother and house were collected through a questionnaire after informed consent signature. Blood samples were tested for anti-HAV antibodies. Antibody titers ≥10 mIU/mL were considered seroprotective. Logistic regression analysis was done to evaluate associations between different variables and seroprotection.

Results. Of 1119 children included, 97.0% lived in urban areas, 92.7% had safe water access and 57.8% had sewers at home. Mean age was 10.7 years, and the mean post-vaccination interval was 9.7 years (Range: 9.0–11.3 years). Of the total, 87.6% had protective antibodies against HAV. Higher seroprotection rates were observed in Santa Fe compared with the global rate (91.9% vs. 87.6%; OR 1.94 (95% CI: 1.27–2.95); P = 0.002). In contrast, lowest rates resulted in San Justo, Buenos Aires (81.4% vs. 87.6% OR 0.45 (95% CI: 0.32–0.65); P < 0.001). No association between socio-economic variables and seroprotection was found. Geometric mean concentration (GMC) of HAV Ab titers was 28.0 mIU/mL (95% CI: 26.8–29.3 mIU/mL).

Conclusion. Single-dose universal hepatitis A immunization in infants resulted in sustained immunologic protection up to 11 years in Argentina. Lower seroprevalence rates in San Justo have no clear reason and were not associated with an increase in HAV cases in that area. These findings, along with the low current disease burden confirm the success of the intervention.

Disclosures. All authors: No reported disclosures.

1057. No Viral Spreading After Rotavirus Vaccination in NICU

Hirokyu Hiramatsu, MS¹; Ryota Suzuki, PhD²; Shigeki Yamada, PhD¹; Masaru Ihira, PhD³; Arisa Nagatani, MD⁴; Masafumi Miyata, MD⁴; Hiroki Miura, MD⁴; Fumihiko Hattori, MD⁴; Ken Sugata, MD⁴; Koki Taniguchi, PhD⁵; Naoko Nishimura, MD⁶; Takao Ozaki, MD⁶ and Tetsushi Yoshikawa, MD⁷; ¹Pharmacy, Fujita Health University Hospital, Toyoake, Japan, ²Fujita Health University, Toyoake, Japan, ³Faculty of Clinical Engineering, Fujita Health University, Toyoake, Japan, ⁴Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan, ⁵Department of Virology and Parasitology, Fujita Health University, Toyoake, Japan, ⁶Department of Pediatrics, Konan Kosei Hosp., Konan, Japan, ⁷Pediatrics, Fujita Health University, Toyoake, Japan

Session: 140. Assorted Pediatric Vaccines

Friday, October 6, 2017: 12:30 PM

Background. Preterm and low birth weight infants are considered to be high risk for severe rotavirus gastroenteritis. However, it has been demonstrated that many infants are ineligible for receiving rotavirus vaccine due to over the age limitation within the neonatal intensive care unit (NICU). We sought to elucidate the safety of rotavirus (RV) vaccination in NICU by assessing vaccine virus transmission from vaccine recipients in NICU.

Methods. This study was designed as the prospective study conducted at the NICU of Fujita Health University hospital and Konan Kosei Hospital. This study was approved by the ethical committee in our university. Premature age-eligible infants were recruited to administer rotavirus vaccine. Stool samples were serially collected from unvaccinated infants (UVI) and vaccinated infants (VI) who received either the pentavalent rotavirus vaccine (RV5) or monovalent rotavirus vaccine (RV1). During October 10, 2014 and December 25, 2015, 19 VIs and 49 UVIs were enrolled in this study. Contact precaution was carried out in NICU. All stool samples were analyzed by real-time RT-PCR for detection of RV5, RV1, and wild-type strain's genomes.